110 related articles for article (PubMed ID: 32758617)
21. IKKβ targeting reduces KRAS-induced lung cancer angiogenesis in vitro and in vivo: A potential anti-angiogenic therapeutic target.
Carneiro-Lobo TC; Scalabrini LC; Magalhães LDS; Cardeal LB; Rodrigues FS; Dos Santos EO; Baldwin AS; Levantini E; Giordano RJ; Bassères DS
Lung Cancer; 2019 Apr; 130():169-178. PubMed ID: 30885340
[TBL] [Abstract][Full Text] [Related]
22. Adverse Event Management in Patients with
Chalmers A; Cannon L; Akerley W
Oncologist; 2019 Jul; 24(7):963-972. PubMed ID: 30598499
[TBL] [Abstract][Full Text] [Related]
23. Dabrafenib plus trametinib in patients with previously untreated BRAF
Planchard D; Smit EF; Groen HJM; Mazieres J; Besse B; Helland Å; Giannone V; D'Amelio AM; Zhang P; Mookerjee B; Johnson BE
Lancet Oncol; 2017 Oct; 18(10):1307-1316. PubMed ID: 28919011
[TBL] [Abstract][Full Text] [Related]
24. The superior efficacy of anti-PD-1/PD-L1 immunotherapy in KRAS-mutant non-small cell lung cancer that correlates with an inflammatory phenotype and increased immunogenicity.
Liu C; Zheng S; Jin R; Wang X; Wang F; Zang R; Xu H; Lu Z; Huang J; Lei Y; Mao S; Wang Y; Feng X; Sun N; Wang Y; He J
Cancer Lett; 2020 Feb; 470():95-105. PubMed ID: 31644929
[TBL] [Abstract][Full Text] [Related]
25. Coadministration of Trametinib and Palbociclib Radiosensitizes KRAS-Mutant Non-Small Cell Lung Cancers In Vitro and In Vivo.
Tao Z; Le Blanc JM; Wang C; Zhan T; Zhuang H; Wang P; Yuan Z; Lu B
Clin Cancer Res; 2016 Jan; 22(1):122-33. PubMed ID: 26728409
[TBL] [Abstract][Full Text] [Related]
26. A Phase 1/1b Study Evaluating Trametinib Plus Docetaxel or Pemetrexed in Patients With Advanced Non-Small Cell Lung Cancer.
Gandara DR; Leighl N; Delord JP; Barlesi F; Bennouna J; Zalcman G; Infante JR; Reckamp KL; Kelly K; Shepherd FA; Mazieres J; Janku F; Gardner OS; Mookerjee B; Wu Y; Cox DS; Schramek D; Peddareddigari V; Liu Y; D'Amelio AM; Blumenschein G
J Thorac Oncol; 2017 Mar; 12(3):556-566. PubMed ID: 27876675
[TBL] [Abstract][Full Text] [Related]
27. Small Molecule KRAS Agonist for Mutant KRAS Cancer Therapy.
Xu K; Park D; Magis AT; Zhang J; Zhou W; Sica GL; Ramalingam SS; Curran WJ; Deng X
Mol Cancer; 2019 Apr; 18(1):85. PubMed ID: 30971271
[TBL] [Abstract][Full Text] [Related]
28. MEK inhibitor GSK1120212-mediated radiosensitization of pancreatic cancer cells involves inhibition of DNA double-strand break repair pathways.
Estrada-Bernal A; Chatterjee M; Haque SJ; Yang L; Morgan MA; Kotian S; Morrell D; Chakravarti A; Williams TM
Cell Cycle; 2015; 14(23):3713-24. PubMed ID: 26505547
[TBL] [Abstract][Full Text] [Related]
29. DNA vaccine elicits an efficient antitumor response by targeting the mutant Kras in a transgenic mouse lung cancer model.
Weng TY; Yen MC; Huang CT; Hung JJ; Chen YL; Chen WC; Wang CY; Chang JY; Lai MD
Gene Ther; 2014 Oct; 21(10):888-96. PubMed ID: 25077772
[TBL] [Abstract][Full Text] [Related]
30. Targeting oncogenic protein kinase Cι for treatment of mutant KRAS LADC.
Fields AP; Ali SA; Justilien V; Murray NR
Small GTPases; 2017 Jan; 8(1):58-64. PubMed ID: 27245608
[TBL] [Abstract][Full Text] [Related]
31. Targeting of MEK in lung cancer therapeutics.
Heigener DF; Gandara DR; Reck M
Lancet Respir Med; 2015 Apr; 3(4):319-27. PubMed ID: 25801412
[TBL] [Abstract][Full Text] [Related]
32. Blocking STAT3 by pyrvinium pamoate causes metabolic lethality in KRAS-mutant lung cancer.
Feng J; Jiang W; Liu Y; Huang W; Hu K; Li K; Chen J; Ma C; Sun Z; Pang X
Biochem Pharmacol; 2020 Jul; 177():113960. PubMed ID: 32298693
[TBL] [Abstract][Full Text] [Related]
33. Combined treatment of ABT199 and irinotecan suppresses KRAS-mutant lung cancer cells.
Xu Y; Zong S; Gao X; Zhang H; Wang B; Li P; Liu T; Li S
Gene; 2019 Mar; 688():1-6. PubMed ID: 30415007
[TBL] [Abstract][Full Text] [Related]
34. IL-17C-mediated innate inflammation decreases the response to PD-1 blockade in a model of Kras-driven lung cancer.
Ritzmann F; Jungnickel C; Vella G; Kamyschnikow A; Herr C; Li D; Menger MM; Angenendt A; Hoth M; Lis A; Bals R; Beisswenger C
Sci Rep; 2019 Jul; 9(1):10353. PubMed ID: 31316109
[TBL] [Abstract][Full Text] [Related]
35. Preclinical Efficacy of Covalent-Allosteric AKT Inhibitor Borussertib in Combination with Trametinib in
Weisner J; Landel I; Reintjes C; Uhlenbrock N; Trajkovic-Arsic M; Dienstbier N; Hardick J; Ladigan S; Lindemann M; Smith S; Quambusch L; Scheinpflug R; Depta L; Gontla R; Unger A; Müller H; Baumann M; Schultz-Fademrecht C; Günther G; Maghnouj A; Müller MP; Pohl M; Teschendorf C; Wolters H; Viebahn R; Tannapfel A; Uhl W; Hengstler JG; Hahn SA; Siveke JT; Rauh D
Cancer Res; 2019 May; 79(9):2367-2378. PubMed ID: 30858154
[TBL] [Abstract][Full Text] [Related]
36. An Acquired NRAS Q61K Mutation in BRAF V600E-Mutant Lung Adenocarcinoma Resistant to Dabrafenib Plus Trametinib.
Abravanel DL; Nishino M; Sholl LM; Ambrogio C; Awad MM
J Thorac Oncol; 2018 Aug; 13(8):e131-e133. PubMed ID: 29631033
[No Abstract] [Full Text] [Related]
37. Phase II study of the GI-4000 KRAS vaccine after curative therapy in patients with stage I-III lung adenocarcinoma harboring a KRAS G12C, G12D, or G12V mutation.
Chaft JE; Litvak A; Arcila ME; Patel P; D'Angelo SP; Krug LM; Rusch V; Mattson A; Coeshott C; Park B; Apelian DM; Kris MG; Azzoli CG
Clin Lung Cancer; 2014 Nov; 15(6):405-10. PubMed ID: 25044103
[TBL] [Abstract][Full Text] [Related]
38. KRAS-mutation status dependent effect of zoledronic acid in human non-small cell cancer preclinical models.
Kenessey I; Kói K; Horváth O; Cserepes M; Molnár D; Izsák V; Dobos J; Hegedűs B; Tóvári J; Tímár J
Oncotarget; 2016 Nov; 7(48):79503-79514. PubMed ID: 27780929
[TBL] [Abstract][Full Text] [Related]
39. Targeting glycan sulfation in a CD11c+ myeloid population inhibits early KRAS-mutant lung neoplasia.
Kim SY; Johns SC; Gupta P; Varki N; Fuster MM
Neoplasia; 2021 Nov; 23(11):1137-1143. PubMed ID: 34715561
[TBL] [Abstract][Full Text] [Related]
40. The EGFR-specific antibody cetuximab combined with chemotherapy triggers immunogenic cell death.
Pozzi C; Cuomo A; Spadoni I; Magni E; Silvola A; Conte A; Sigismund S; Ravenda PS; Bonaldi T; Zampino MG; Cancelliere C; Di Fiore PP; Bardelli A; Penna G; Rescigno M
Nat Med; 2016 Jun; 22(6):624-31. PubMed ID: 27135741
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
